Trials / Completed
CompletedNCT06926673
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 3
A Phase II, Randomized, Open-label Platform Trial Utilizing a Master Protocol to Study Novel Regimens Versus Standard of Care Treatment in NSCLC Participants
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 62 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is a sub-study of the master protocol 205801 (NCT03739710). This sub study will assess safety and pharmacokinetics and pharmacodynamics (PK/PD) of novel regimens (Dostarlimab plus belrestotug , and Dostarlimab plus belrestotug plus nelistotug) in participants with previously treated NSCLC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dostarlimab | Dostarlimab will be administered |
| DRUG | Belrestotug. | Belrestotug will be administered |
| DRUG | Nelistotug | Nelistotug will be administered. |
Timeline
- Start date
- 2021-12-23
- Primary completion
- 2024-05-02
- Completion
- 2024-05-02
- First posted
- 2025-04-14
- Last updated
- 2025-07-03
- Results posted
- 2025-07-03
Locations
15 sites across 6 countries: United States, Canada, France, Germany, Italy, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06926673. Inclusion in this directory is not an endorsement.